Abstracts tagged "Intervention"

Abstract Number: 1965 • ACR Convergence 2025
Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
Rabia Deniz¹, Tevfik Güzelbey², İlhan Nahit Mutlu², Kübra Kalkan³, Özgür Kılıçkesmez² and Cemal Bes⁴, ¹University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ²University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Radiology, Istanbul, Turkey, ³University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, ⁴University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
Background/Purpose: Recurrent monoarthritis (RM) is a significant therapeutic challenge in rheumatology, often persisting despite NSAIDs, corticosteroids (CS), DMARDs, and biologic therapies. Local interventions like intra-articular…
Abstract Number: 1832 • ACR Convergence 2025
Time-to-Event Analysis of Statin Use and Thrombotic Risk in Patients with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
Christine Lenchur¹, Niurka Liranzo Tejera¹, Adal Abonamah¹, Takemichi Matsui¹, Emily Cosentino¹, Priscilla Abate Namnum², Olga Marushchak¹, Melissa Akselrad¹, Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde³, Harleen Sidhu⁶, Emilia Bagiella⁵, Ian Wright⁵ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) face elevated risk of thrombotic events (TEs) due to traditional cardiovascular factors and chronic inflammation. Statins may offer…
Abstract Number: 1586 • ACR Convergence 2025
Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
Stefano Di Donato¹, Marie-Elise Truchetet², Marco Minerba³, Oliver Distler⁴, JUAN JOSE ALEGRE SANCHO⁵, Yolanda Braun Moscovici⁶, Christina Bergmann⁷, Petros Sfikakis⁸, Jeska de Vries-Bouwstra⁹, Murray Baron¹⁰, Silvia Bellando-Randone¹¹, Lorenzo Dagna¹², Christopher Denton¹³, Madelon Vonk¹⁴, Vanessa Smith¹⁵, Ivan Castellvi¹⁶, Gabriela Riemekasten¹⁷, Andra Balanescu¹⁸, Masataka Kuwana¹⁹, Maria De Santis²⁰, Kamal Solanki²¹, Anastas Batalov²², Vahan Mukuchyan²³, Marco Matucci-Cerinic²⁴, Yannick Allanore²⁵, Francesco Del Galdo²⁶ and Michael Hughes²⁷, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁵Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rambam Heath Care Campus, Haifa, Israel, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁸NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Self employed, Montréal, Canada, ¹¹University of Florence, Florence, Florence, Italy, ¹²Ospedale San Raffaele, Milano, Italy, ¹³University College London, UK, London, United Kingdom, ¹⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁵Ghent University Hospital, Gent, Belgium, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁷University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁸UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ¹⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁰Humanitas University, Pieve Emanuele, Italy, ²¹Waikato Hospital, Hamilton, New Zealand, ²²Medical University of Plovdiv, Plovdiv, Bulgaria, ²³"Erebuni" Medical Center, Yerevan, Armenia, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Université Paris Cité, Paris, France, ²⁶University of Leeds, Leeds, United Kingdom, ²⁷Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease characterized by vasculopathy, fibrosis, and immune dysregulation. While JAK inhibitors (JAKi) have shown promising immunomodulatory…
Abstract Number: 1587 • ACR Convergence 2025
Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
Stefano Di Donato¹, JUAN JOSE ALEGRE SANCHO², Anastas Batalov³, Zguro Batalov⁴, Silvia Bellando-Randone⁵, carmela coccia⁶, Marco de Pinto⁷, Dilia Giuggioli⁸ and Michael Hughes⁹, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ³Medical University of Plovdiv, Plovdiv, Bulgaria, ⁴UMHAT Kaspela, Ploudiv, Bulgaria, ⁵University of Florence, Florence, Florence, Italy, ⁶Rheumatology Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy, ⁷Azienda Ospedaliero Universitaria Policlinico di Modena, Parma, Parma, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: JAK inhibitors (JAKi) have shown promising early results in systemic sclerosis (SSc) patients, yet real-world data on their longitudinal effects across different disease domains…
Abstract Number: 1246 • ACR Convergence 2025
Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial
seda yildiz¹, bugra ince¹ and Halil ibrahim candal², ¹izmir sehir hastanesi, izmir, Turkey, ²ızmir sehir hastanesi, izmir
Background/Purpose: Experimental and clinical studies suggest that fascial structures play a critical role in the pathogenesis and pain mechanisms of myofascial pain syndrome (MTrP). It…
Abstract Number: 1190 • ACR Convergence 2025
IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort
Xinli Yang¹, Wen Zhang², Jiaxin zhou³ and Yuxue Nie⁴, ¹Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ²Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ³Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Dong Cheng Qu, China (People's Republic)
Background/Purpose: This study aimed to explore the clinical characteristics, treatment, and prognosis of IgG4-related disease (IgG4-RD) patients with comorbid autoimmune diseases (AIDs).Methods: A total of…
Abstract Number: 1182 • ACR Convergence 2025
Cardiac Sarcoidosis in Black Patients: A Biopsy-Confirmed Cohort Study
Roshan Subedi¹, Haya Haddad², Rachel Barish¹, Tania Vora¹, Nana Afari-Armah³, Ajay Kadakkal¹, Farooq Sheikh¹ and Florina Constantinescu¹, ¹Medstar Washington Hospital Center, Washington, DC, ²Medstar Washington Hospital Center, Silver Spring, MD, ³Medstar Washington Hospital Center, Washington
Background/Purpose: Sarcoidosis is an inflammatory disease characterized by non-necrotizing granulomatous inflammation that can affect any organ. Approximately 5% of patients with sarcoidosis develop clinically significant…
Abstract Number: 0974 • ACR Convergence 2025
Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
Xuezhi Hong¹, Yanhua Xiao², shihao zhu³, Yi-Nan Li⁴, Linlin Huang³, Martin Regensburger⁵, Franz Marxreiter⁶, Tim Filla⁷, Andrea-Hermina Györfi⁸, James Adjaye⁹, Jürgen Winkler⁶, Florian Groeber-Becker¹⁰, Jörg Distler¹¹ and Alexandru-Emil Matei¹², ¹Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, Düsseldorf, Germany, ²Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, ³Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵Department of Stem Cell Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁶Department of Molecular Neurology, FAU Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Institute for Stem Cell Research and Regenerative Medicine, University Hospital Düsseldorf, Moorenstrasse ⁵, D-⁴⁰²²⁵ Duesseldorf, Germany, Dusseldorf, Germany, ¹⁰Department of Ophthalmology, University Hospital Düsseldorf, ⁴⁰²²⁵, Düsseldorf, Germany, Dusseldorf, Germany, ¹¹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany
Background/Purpose: Previous studies showed that monocyte-derived macrophages become pro-fibrotic in systemic sclerosis (SSc) and contribute to fibroblast activation. Macrophages are, however, a heterogeneous population. Macrophages…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
Abstract Number: 0209 • ACR Convergence 2025
A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
Yuanteng Li¹, Cheuk Leung², Heather Lin², Angeles Lopez-Olivio³ and Jean Tayar³, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson Cancer Center, Houston, ³The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Arthrocentesis and joint injections are commonly performed to diagnose and to treat rheumatic conditions such as crystal-induced arthritis, septic arthritis, and inflammatory arthritis. While…
Abstract Number: 2690 • ACR Convergence 2025
Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Lihi Eder¹, Sohan Shahab², Sarah Hopkins Gillespie³, Laura Bumbulis⁴, Helen Emanoilidis⁵, Charlene Compher⁶, Jose Scher⁷, Dafna D. Gladman⁸, Richard Cook⁴, Vinod Chandran¹ and Alexis Ogdie⁹, ¹University of Toronto, Toronto, ON, Canada, ²Women’s College Research Institute, Women’s College Hospital, Toronto, Canada, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Waterloo, Waterloo, Canada, ⁵Women’s College Hospital, Toronto, Canada, ⁶University of Pennsylvania School of Nursing and Hospital of the University of Pennsylvania, Philadelphia, ⁷New York University School of Medicine, New York, NY, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: The Dietary Interventions in Psoriatic Arthritis (DIPSA) study is a multicentre randomized controlled trial (RCT) designed to evaluate the efficacy of two personalized dietary…
Abstract Number: 2687 • ACR Convergence 2025
Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
Lihi Eder¹, Uma Scher², Kyra Chen³, Alexandra L. Rice³, Sydney Thib⁴ and Rebecca Haberman⁵, ¹University of Toronto, Toronto, ON, Canada, ²NYU School of Medicine, Scarsdale, NY, ³NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ⁴Women's College Research Institute, Women's College Hospital, Toronto, Canada, ⁵NYU Langone Health, New York, NY
Background/Purpose: Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with reduced therapeutic response, worse disease outcomes, and increased cardiometabolic risk. Glucagon-like peptide-1…
Abstract Number: 2524 • ACR Convergence 2025
Rituximab in the Treatment of Susac Syndrome: Single Center Descriptive Study with a Large Susac Cohort
Adam Brown¹, Leonard Calabrese² and Rula Hajj-Ali³, ¹Cleveland Clinic, Shaker Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Cleveland
Background/Purpose: Susac Syndrome is a rare autoimmune condition causing microvascular occlusions in the brain, retina and inner ear leading to the characteristic triad of encephalopathy,…
Abstract Number: 2280 • ACR Convergence 2025
Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
Athanasios Mavropoulos¹, Christos Liaskos², Ioannis Alexiou³, Christina Katsiari⁴, Dimitrios Bogdanos⁵ and Lazaros Sakkas⁶, ¹University of Thessaly, Volos, Greece, ²University of Thessaly, Faculty of Medicine, Larisa, Greece, ³University General Hospital of larissa, Larissa, Greece, ⁴University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁵Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece, ⁶Department of Rheumatology, University of Thessaly, Larissa, Greece
Background/Purpose: Abatacept, an efficacious therapy for rheumatoid arthritis (RA), inhibits the interaction between CD28 on T cells and CD80/CD86 on antigen-presenting cells (APCs). The aim…
Abstract Number: 2187 • ACR Convergence 2025
Transforming MSUS Access in Mexico: A Comparative Study of National Trends and a Hybrid Training Cohort
Mario R. Garcia-Pompermayer¹, SARAH G. AYTON², Karina Silva Luna³, Ricardo Ramirez-Morales⁴ and Mario Garza Elizondo⁵, ¹Hospital San Jose Tecnologico de Monterrey, Monterrey, Mexico, ²Columbia University, New York, NY, ³Centro Médico Zambrano Hellion, Monterrey, Mexico, ⁴Private Rheumatology Practice, Monterrey, Mexico, Monterrey, Nuevo Leon, Mexico, ⁵Hospital Zambrano-Hellion TecSalud, Monterrey, Mexico
Background/Purpose: Musculoskeletal ultrasound (MSUS) is a valuable diagnostic tool in rheumatology, yet access to formal MSUS training in Latin America remains limited. In a 2022…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].